
Access to DRDO drug 2-DG will improve in weeks: Dr. Reddy’s
The Hindu
DRDO invites more pharma firms to take up its production
Availability of 2-Deoxy-D-Glucose (2-DG), the drug developed by DRDO lab INMAS and approved for use as adjunct in treatment of moderate to severe COVID-19 patients, is set to improve in the weeks ahead with drugmaker Dr. Reddy’s Laboratories ramping up production. “I expect a very significant ramp up in the second half of June and subsequently in July,” said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s. Stating that the company is licensee of DRDO, for the product launched last month following emergency use authorisation from the Drugs Controller General of India, he said in a matter of weeks the capacity will be enhanced to meet requirements of lakhs of patients.
On December 23, the newly elected office bearers of the Anna Nagar Towers Club, led by its president ‘Purasai’ B. Ranganathan, who is a former MLA, met with Tamil Nadu Chief Minister M. K. Stalin and conveyed their greetings. According to a press release, besides, ‘Purasai’ B. Ranganathan, the Anna Nagar Towers Club delegation that met Stalin at Anna Arivalayam, the DMK Party headquarters, included vice-president R. Sivakumar, secretary R. Muralibabu, joint secretary D. Manojkumar, treasurer K. Jayachandran and executive committee members N. D. Avinash, K. Kumar, N. R. Madhurakavi, K. Mohan, U. Niranjan, S. Parthasarathi, K. Rajasekar, S. Rajasekar, M. S. Ramesh, R. Satheesh, N. C. Venkatesan and K. Yuvaraj. Karthik Mohan, deputy secretary of DMK’s Information Technology Wing, was present on the occasion.












